INKT - MiNK Therapeutics, I...

WACOC of MiNK Therapeutics, Inc.(INKT), MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, devel

MiNK Therapeutics, Inc.

INKT

NASDAQ

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

0.872 USD

-0.0452 (-5.19%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

Operating Data Balance Sheet Free Cash Flow Free Cash Flow Buildup Terminal Value Intrinsic Value WACC

FMP

Home Terms of Service Privacy Policy Blog Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.